Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases
HOUSTON, Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Plus Therapeutics, Inc. ( Nasdaq: PSTV ) ( the "Company" ) , a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system ( CNS ) cancers, announced it has completed a Type B meeting ...
How this was made
The 30-second read
Why it matters
Successful FDA engagement could accelerate clinical development and commercialization timelines.
Market read
The news is highly relevant to investors and stakeholders in biotech and CNS cancer treatment sectors.
What to watch
Possible delays in clinical development or unforeseen regulatory hurdles could negate positive expectations.
Background
Plus Therapeutics is advancing REYOBIQ™ for leptomeningeal metastases, a challenging CNS cancer indication.
Ticker impact
The news pertains to Plus Therapeutics Inc., which is directly linked to the ticker PSTV.
Moderate upward movement expected in the short term, around 5-10%.
The completion of a key FDA meeting is a significant milestone; however, the lack of immediate clinical trial results or approval means the impact may be limited and subject to market sentiment.
Market effects
Potential positive influence on biotech companies developing CNS cancer treatments.
Limited to U.S. biotech sector; broader regional impact minimal.
Low; primarily relevant to U.S. biotech industry and investors.
Counterpoint
Market may have already priced in the FDA meeting news, leading to limited upside or potential short-term correction.
Key entities
- CompanyPlus Therapeutics Inc.
A biotech firm specializing in CNS cancer diagnostics and therapeutics.
- Drug CandidateREYOBIQ™
A radiopharmaceutical developed for CNS cancer treatment.



